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Introduction {#sec005}
============

Microvascular dysfunction is an important underlying mechanism in common diseases that are partly or wholly of *microvascular* origin such as heart failure \[[@pone.0187324.ref001]\], (lacunar) stroke \[[@pone.0187324.ref002]\], depression \[[@pone.0187324.ref003]\], cognitive decline \[[@pone.0187324.ref004]\], retinopathy \[[@pone.0187324.ref005]\], chronic kidney disease \[[@pone.0187324.ref006]\], and neuropathy \[[@pone.0187324.ref005]\].

However, determinants of microvascular dysfunction in the general population are mostly unknown. Although several studies \[[@pone.0187324.ref007]--[@pone.0187324.ref013]\] have investigated potential determinants of microvascular function, these studies were conducted in small numbers of highly selected individuals \[[@pone.0187324.ref007]--[@pone.0187324.ref013]\] and were insufficiently adjusted \[[@pone.0187324.ref007]--[@pone.0187324.ref013]\] for potential confounders, which limits translation to the general population.

In the general population, age, sex, hypertension, dyslipidemia, hyperglycemia, obesity, and smoking are major determinants of *macrovascular* diseases (e.g. stroke, myocardial infarction and peripheral artery disease) \[[@pone.0187324.ref014]\], and have been shown to act through inducing large artery endothelial dysfunction \[[@pone.0187324.ref015], [@pone.0187324.ref016]\]. However, this does not necessarily imply that microvascular (endothelial) function is affected similarly, as microvascular function is the result of the complex interrelationships among structure and function of vessel wall components (matrix, smooth muscle cells, and endothelium), which are also closely related to metabolic and neurogenic influences \[[@pone.0187324.ref017]--[@pone.0187324.ref021]\]. In addition, endothelial cells are known to be heterogeneous, depending on their localization \[[@pone.0187324.ref022]\]. Nevertheless, many of the risk factors for macrovascular diseases are also associated with microvascular diseases \[[@pone.0187324.ref023]--[@pone.0187324.ref026]\]. Thus, we hypothesized that these risk factors may also be determinants of microvascular (endothelial) function.

Therefore, this study aimed to determine, in a population-based setting, whether cardiovascular risk factors were associated with, and thus potential determinants of, retinal and skin microvascular (endothelial) function. We chose retina and skin because these are unique sites enabling direct and reproducible \[[@pone.0187324.ref027], [@pone.0187324.ref028]\] assessment of microvascular function, as measured by flicker light-induced retinal arteriolar dilation and heat-induced skin hyperemia.

Methods {#sec006}
=======

Study population and design {#sec007}
---------------------------

We used data from The Maastricht Study, an observational prospective population-based cohort study. The rationale and methodology have been described previously \[[@pone.0187324.ref029]\]. In brief, the study focuses on the etiology, pathophysiology, complications and comorbidities of type 2 diabetes and is characterized by an extensive phenotyping approach. Eligible for participation were all individuals aged between 40 and 75 years and living in the southern part of the Netherlands. Participants were recruited through mass media campaigns and from the municipal registries and the regional Diabetes Patient Registry via mailings. Recruitment was stratified according to known type 2 diabetes status, with an oversampling of individuals with type 2 diabetes, for reasons of efficiency. The present report includes cross-sectional data from the first 3451 participants, who completed the baseline survey between November 2010 and September 2013. The examinations of each participant were performed within a time window of three months. The study has been approved by the institutional medical ethical committee (NL31329.068.10) and the Minister of Health, Welfare and Sports of the Netherlands (Permit 131088-105234-PG). All participants gave written informed consent.

Assessment of microvascular function {#sec008}
------------------------------------

All participants were asked to refrain from smoking and drinking caffeine-containing beverages three hours before the measurement. A light meal (breakfast and (or) lunch), low in fat content, was allowed if taken at least 90 minutes prior to the start of the measurements.

Retinal arteriolar vasodilation to flicker light exposure was measured by the Dynamic Vessel Analyzer (Imedos, Jena, Germany). Briefly, a baseline recording of 50 seconds was followed by 40-second flicker light exposure followed by a 60-second recovery period. Baseline diameter was calculated as the average diameter size of the 20--50 seconds recording and was expressed in measurement units (MU). Percentage dilation over baseline was based on the average dilation achieved at time points 10 and 40 seconds during the flicker stimulation period.

Heat-induced skin hyperemia was measured by laser-Doppler flowmetry (Perimed, Järfälla, Sweden). Briefly, skin blood flow, expressed in arbitrary perfusion units (PU), was recorded unheated for 2 minutes to serve as a baseline. After 2 minutes, the temperature of the laser-Doppler probe was rapidly and locally increased to 44°C, and was kept constant until the end of the registration. The heat-induced skin hyperemic response was expressed as the percentage increase in average PU during the 23 minutes heating phase over the 2 minutes average baseline PU. Both measurements have extensively been described previously \[[@pone.0187324.ref030]\]; more details are provided in the [S1 Appendix](#pone.0187324.s001){ref-type="supplementary-material"}.

Definition of cardiovascular risk factors {#sec009}
-----------------------------------------

Cardiovascular risk factors considered were age, sex, waist circumference, fasting plasma glucose (FPG), total-to-high-density lipoprotein (HDL) cholesterol ratio, 24-h systolic blood pressure (SBP), and smoking status. We also considered lipid-modifying and antihypertensive medication.

Measurement of cardiovascular risk factors {#sec010}
------------------------------------------

We determined body mass index, waist circumference, glucose levels, glycated hemoglobin A1c (HbA1c), 24-h ambulatory systolic and diastolic blood pressure (DBP), total and HDL cholesterol, and triglycerides as described previously \[[@pone.0187324.ref029]\] and detailed in the [S2 Appendix](#pone.0187324.s002){ref-type="supplementary-material"}. Smoking status (never, former, current) and pack-years of smoking were assessed by web-based questionnaire \[[@pone.0187324.ref029]\]. Glucose metabolism status was defined according to the World Health Organization 2006 criteria, based on a standardized 2-h 75 gram oral glucose tolerance test ([S2 Appendix](#pone.0187324.s002){ref-type="supplementary-material"}).

Measurement of covariates {#sec011}
-------------------------

The use of lipid-modifying and antihypertensive medication was assessed during a medication interview where generic name, dose, and frequency were registered \[[@pone.0187324.ref029]\]. The assessment of a history of cardiovascular disease (CVD), 24-h urinary albumin excretion, estimated glomerular filtration rate (eGFR), and the presence of retinopathy have been described previously \[[@pone.0187324.ref029]\] (cf. the [S3 Appendix](#pone.0187324.s003){ref-type="supplementary-material"}).

Statistical analysis {#sec012}
--------------------

All analyses were performed with Statistical Package for Social Sciences version 23.0 (IBM SPSS, Armonk, USA). Variables with a skewed distribution (diabetes duration and pack-years of smoking) were log10 transformed. A Pearson correlation coefficient was used to assess the correlation between flicker light-induced retinal arteriolar %-dilation and heat-induced skin %-hyperemia. Standardized multiple linear regression analyses were used to evaluate the association of cardiovascular risk factors (age, sex, waist circumference, FPG, total-to-HDL cholesterol ratio, 24-h SBP, and smoking status) with both retinal and skin microvascular function. To compare regression coefficients between cardiovascular risk factors, continuous measures of these risk factors were standardized into z-scores before analyses. Associations of cardiovascular risk factors were adjusted for each other and for additional covariates (the use of antihypertensive and lipid-modifying medication, a history of CVD, 24-h urinary albumin excretion, eGFR, and the presence of retinopathy). In additional analyses, FPG was substituted by HbA1c, 2-h postload or by type 2 diabetes (T2DM) (yes/no). Waist circumference was substituted by body mass index, and 24-h SBP by 24-h DBP, 24-h mean arterial pressure or 24-h pulse pressure.

Data were expressed as standardized regression coefficients and their 95% confidence interval (95%CI). A P-value \<0.05 was considered statistically significant. The study, by design, oversampled individuals with T2DM; we therefore investigated potential interactions between cardiovascular risk factors and T2DM by adding interaction terms (the product of a cardiovascular risk factor and T2DM) to the regression models. Similarly, interactions between the cardiovascular risk factors and sex were investigated (the product of a cardiovascular risk factor and sex). A P~interaction~\<0.10 was considered statistically significant. A P~interaction~≥0.10 indicates that the association between a cardiovascular risk factor and retinal or skin microvascular function does not statistically significantly differ between individuals without and with T2DM, or between women and men, respectively \[[@pone.0187324.ref031]\]. A non-significant P~interaction~ between a cardiovascular risk factor and T2DM therefore indicates that the association between that cardiovascular risk factor and retinal or skin microvascular function was not driven by the oversampling of individuals with T2DM. This implies that any associations observed in this T2DM-enriched population can be considered valid for a non-oversampled population, i.e. the general population \[[@pone.0187324.ref031]\]. Collinearity diagnostics (i.e. tolerance \<0.10 and/or variance inflation factor \>10) were used to detect multicollinearity between the cardiovascular risk factors and covariates.

Results {#sec013}
=======

Study population {#sec014}
----------------

From the initial 3451 participants, retinal arteriolar reactivity data was available in 2290. The reasons for missing data were logistical (n = 891), insufficient measurement quality (n = 209) or contraindications (n = 61). Data on cardiovascular risk factors were missing in 299 participants, particularly on 24-h blood pressure (n = 260), mainly due to device availability. The population in which retinal arteriolar reactivity data were available thus consisted of 1991 participants. Heat-induced skin hyperemia data were available in 1676 of the 3451 participants. The reasons for missing data were logistical (n = 1662) or insufficient measurement quality (n = 113). Cardiovascular risk factors were missing in 249 participants, mainly due to missing 24-h blood pressure values (n = 201). The population in which heat-induced skin hyperemia data were available thus consisted of 1427 participants ([Fig 1](#pone.0187324.g001){ref-type="fig"} shows the flow chart).

![Retinal and skin study population selection.\
\* = Logistical reasons: no Dynamic Vessel Analyzer equipment available (n = 536), no trained researcher available (n = 232), no eye drops given for traffic safety reasons (n = 123); † = Contraindicated: history of epilepsy (n = 14), allergy to eye drops (n = 33), glaucoma or lens implants (n = 14); ‡ = Logistical reasons: no laser-Doppler equipment available (n = 354), no trained researcher available (n = 271), technical failure (n = 1037). § = Missing values on cardiovascular risk factors were not mutually exclusive.](pone.0187324.g001){#pone.0187324.g001}

[Table 1](#pone.0187324.t001){ref-type="table"} shows general characteristics of the retinal arteriolar reactivity study population stratified into tertiles of retinal arteriolar %-dilation. This study population had a mean ± standard deviation (SD) age of 59.7±8.2 years, 48.8% were women, 12.1% were current smokers, and 27.4% had T2DM. In addition, when compared to individuals in the lowest tertile of retinal arteriolar %-dilation, those in the middle and highest tertiles were on average younger and had lower fasting and 2-h postload glucose levels ([Table 1](#pone.0187324.t001){ref-type="table"}). The skin study population overlapped for 73% with the retinal study population, and was comparable with regard to age, sex, and cardio-metabolic risk profile ([Table 1](#pone.0187324.t001){ref-type="table"}). The Pearson correlation coefficients between retinal arteriolar %-dilation and skin %-hyperemia was Pearson's r = 0.05, P = 0.095. Individuals with missing data on retinal or skin reactivity measurements or measurements of cardiovascular risk factors were generally comparable to individuals included in the study populations with regard to age, sex, and cardiometabolic risk profile ([S1](#pone.0187324.s004){ref-type="supplementary-material"} and [S2](#pone.0187324.s005){ref-type="supplementary-material"} Tables).

10.1371/journal.pone.0187324.t001

###### General characteristics of the retinal and skin study populations according to tertiles of retinal arteriolar %-dilation and skin %-hyperemia.

![](pone.0187324.t001){#pone.0187324.t001g}

                                                            Retinal study population                       Skin study population                                                                                             
  --------------------------------------------------------- -------------------------- ------------------- ----------------------- --------- ------------------------ -------------------------- --------------------------- ---------
  Range of retinal arteriolar %-dilation                    -4.8 to 1.3                1.3 to 4.0          4.0 to 15.2                       \-                       \-                         \-                          \-
  Range of skin %-hyperemia                                 \-                         \-                  \-                      \-        20.8 to 725.8            725.9 to 1286.6            1286.6 to 6763.6            
  Age (years)                                               61.5±7.6                   59.4±8.3            58.3±8.4                \<0.001   61.3±7.7                 60.8±7.9                   58.5±8.4                    \<0.001
  Women                                                     289 (43.7)                 345 (51.9)          337 (50.8)              0.005     164 (34.5)               212 (44.5)                 298 (62.6)                  \<0.001
  \- Postmenopausal                                         234 (84.5)                 256 (79.0)          236 (72.0)              \<0.001   126 (84.0)               154 (79.4)                 198 (72.5)                  \<0.001
  \- Hormone replacement therapy                            6 (0.9)                    6 (0.9)             5 (0.8)                 0.942     2 (0.4)                  4 (0.8)                    9 (1.9)                     0.073
  Glucose metabolism status                                                                                                        \<0.001                                                                                   \<0.001
  \- Normal glucose metabolism                              305 (46.1)                 388 (58.3)          438 (66.0)                        216 (45.5)               249 (52.3)                 298 (62.6)                  
  \- Prediabetes                                            102 (15.4)                 92 (13.8)           98 (14.8)                         74 (15.6)                70 (14.7)                  78 (16.4)                   
  \- Type 2 diabetes                                        242 (36.6)                 178 (26.8)          125 (18.8)                        178 (37.5)               146 (30.7)                 96 (20.2)                   
  \- Other types of diabetes                                13 (2.0)                   7 (1.1)             3 (0.5)                           7 (1.5)                  11 (2.3)                   4 (0.8)                     
  Type 2 diabetes duration (years)                          6.0 \[3.0--13.0\]          5.0 \[3.0--10.0\]   6.0 \[3.0--13.0\]       0.223     5.5 \[3.0--10.5\]        7.0 \[3.0--13.0\]          6.0 \[3.0--10.0\]           0.518
  Body mass index (kg/m^2^)                                 27.4±4.4                   26.7±4.7            26.5±4.2                0.001     26.9±4.1                 27.2±4.4                   26.7±4.6                    0.220
  Weight (kg)                                               80.1±15.5                  78.4±16.2           78.2±15.4               0.047     79.7±14.7                80.3±15.4                  77.2±14.7                   0.003
  Height (cm)                                               170.8±8.7                  171.0±9.0           171.4±8.8               0.399     171.9±8.5                171.5±8.7                  169.9±8.7                   0.001
  Waist circumference (cm)                                                                                                                                                                                                   
  \- Men                                                    102.6±12.3                 100.6±12.2          99.9±10.8               0.007     101.4±11.9               101.7±11.7                 99.2±11.1                   0.063
  \- Women                                                  89.9±12.2                  89.2±13.1           88.0±12.2               0.162     88.8±12.2                90.6±12.6                  90.4±13.3                   0.329
  History of cardiovascular disease                         132 (20.2)                 101 (15.4)          73 (11.1)               \<0.001   91 (19.4)                86 (18.4)                  72 (15.3)                   0.227
  Office SBP (mmHg)                                         136.7±18.0                 134.0±18.4          134.3±17.5              0.013     136.6±17.4               136.0±18.6                 134.6±18.4                  0.210
  Office DBP (mmHg)                                         75.7±9.8                   76.2±10.3           76.9±9.6                0.070     76.3±9.4                 76.4±9.8                   76.7±9.8                    0.770
  Ambulatory 24-h SBP (mmHg)                                119.6±11.5                 119.0±12.4          118.9±10.9              0.477     121.8±11.9               120.0±11.9                 117.5±10.8                  \<0.001
  Ambulatory 24-h DBP (mmHg)                                72.8±7.1                   73.6±7.5            74.1±6.8                0.002     74.0±7.1                 73.5±7.0                   73.4±6.5                    0.375
  Ambulatory 24-h PP (mmHg)                                 46.8±8.9                   45.4±8.8            44.7±7.7                \<0.001   47.8±9.1                 46.6±9.0                   44.1±8.1                    \<0.001
  Ambulatory 24-h MAP (mmHg)                                88.4±7.8                   88.8±8.5            89.0±7.5                0.305     89.9±7.9                 89.0±7.9                   88.1±7.2                    0.002
  Smoking                                                                                                                                                                                                                    
  \- Never / former / current                               198/386/78                 248/328/89          253/337/74              0.005     152/244/79               137/286/53                 180/251/45                  \<0.001
  \- % (never / former / current)                           29.9/58.3/11.8             37.3/49.3/13.4      38.1/50.8/11.1          0.005     32.0/51.4/16.6           28.8/60.1/11.1             37.8/52.7/9.5               \<0.001
  Pack-years of smoking                                     4.6 \[0.0--20.0\]          1.0 \[0.0--17.2\]   0.7 \[0.0--13.0\]       0.001     4.6 \[0.0--22.2\]        6.0 \[0.0--22.5\]          1.3 \[0.0--14.0\]           \<0.001
  Fasting glucose (mmol/l)                                  6.4±2.0                    6.0±1.6             5.8±1.3                 \<0.001   6.4±1.9                  6.1±1.6                    5.8±1.3                     \<0.001
  2-h postload glucose (mmol/l)                             8.6±4.6                    7.9±4.2             7.3±3.8                 \<0.001   8.8±4.7                  8.2±4.2                    7.3±4.0                     \<0.001
  HbA1c (%)                                                 6.1±1.1                    5.8±0.9             5.7±0.7                 \<0.001   6.1±1.1                  6.0±0.9                    5.8±0.8                     \<0.001
  HbA1c (mmol/mol)                                          43.3±11.8                  40.3±9.5            38.8±7.9                \<0.001   43.7±11.7                41.8±9.5                   39.9±8.7                    \<0.001
  Total-to-HDL cholesterol ratio                            3.5±1.1                    3.6±1.2             3.6±1.2                 0.168     3.8±1.1                  3.7±1.2                    3.6±1.1                     0.181
  Total cholesterol (mmol/l)                                5.0±1.2                    5.3±1.2             5.4±1.1                 \<0.001   5.1±1.1                  5.2±1.2                    5.4±1.2                     \<0.001
  HDL cholesterol (mmol/l)                                  1.5±0.5                    1.6±0.5             1.6±0.5                 0.019     1.4±0.5                  1.5±0.5                    1.6±0.5                     \<0.001
  LDL cholesterol (mmol/l)                                  2.9±1.0                    3.1±1.0             3.2±1.0                 \<0.001   2.9±1.0                  3.1±1.1                    3.3±1.1                     \<0.001
  Triglycerides (mmol/l)                                    1.5±0.8                    1.5±0.9             1.3±0.7                 0.001     1.5±0.8                  1.5±1.0                    1.3±0.8                     \<0.001
  Antihypertensive medication use                           305 (46.1)                 257 (38.6)          198 (29.8)              \<0.001   219 (46.1)               211 (44.3)                 163 (34.2)                  \<0.001
  Lipid-modifying medication use                            309 (46.7)                 221 (33.2)          176 (26.5)              \<0.001   209 (44.0)               202 (42.4)                 146 (30.7)                  \<0.001
  Diabetes medication use                                                                                                                                                                                                    
  \- Any type                                               205 (31.0)                 143 (21.5)          98 (14.8)               \<0.001   147 (30.9)               127 (26.7)                 77 (16.2)                   \<0.001
  \- Insulin                                                71 (10.7)                  37 (5.6)            24 (3.6)                \<0.001   42 (8.8)                 41 (8.6)                   22 (4.6)                    0.020
  \- Oral glucose-lowering medication                       180 (27.2)                 131 (19.7)          87 (13.1)               \<0.001   132 (27.8)               112 (23.5)                 67 (14.1)                   \<0.001
  eGFR (ml/min/1.73m^2^)                                    86.7±15.8                  88.5±14.4           89.5±13.5               0.001     87.4±14.7                88.0±14.8                  89.7±13.8                   0.044
  eGFR\<60 ml/min/1.73m^2^                                  45 (6.8)                   25 (3.8)            15 (2.3)                \<0.001   15 (3.2)                 19 (4.0)                   17 (3.6)                    0.780
  (Micro)albuminuria[\*](#t001fn002){ref-type="table-fn"}   78 (11.8)                  42 (6.4)            43 (6.5)                \<0.001   50 (10.6)                42 (8.9)                   25 (5.3)                    0.011
  Retinopathy                                               20 (3.1)                   10 (1.6)            2 (0.3)                 \<0.001   7 (1.6)                  11 (2.6)                   3 (0.7)                     0.099
  Baseline arteriolar diameter (MU)                         119.4±15.0                 115.3±15.5          111.6±15.2              \<0.001   \-                       \-                         \-                          \-
  Arteriolar average dilation (%)                                                                                                                                                                                            
  \- Mean±SD                                                0.2±0.9                    2.6±0.8             6.3±1.8                 \<0.001   \-                       \-                         \-                          \-
  \- Median (interquartile range)                           0.4 \[-0.2--0.8\]          2.6 \[1.9--3.3\]    5.9 \[4.9--7.2\]        \<0.001   \-                       \-                         \-                          \-
  Baseline skin blood flow (PU)                             \-                         \-                  \-                      \-        15.5±8.5                 9.9±4.0                    7.7±2.6                     \<0.001
  Skin hyperemic response (%)                                                                                                                                                                                                
  \- Mean±SD                                                \-                         \-                  \-                      \-        418.2±191.3              992.2±158.9                1976.8±715.6                \<0.001
  \- Median (interquartile range)                           \-                         \-                  \-                      \-        423.5 \[256.1--586.2\]   1002.0 \[852.4--1119.0\]   1757.7 \[1508.7--2196.2\]   \<0.001

Data are reported as mean±SD, median \[interquartile range\], or number (percentages %) as appropriate. SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial pressure; PP, pulse pressure; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; MU, measurement units; PU, perfusion units; SD, standard deviation. P for trend as determined with use of one-way ANOVA for continuous variables and χ^2^-test for categorical variables.

\* = (Micro)albuminuria was defined as a urinary albumin excretion of \>30 mg per 24 hours.

Age, sex and retinal arteriolar dilation and skin hyperemia {#sec015}
-----------------------------------------------------------

Age was inversely associated with retinal arteriolar %-dilation and skin %-hyperemia; per SD higher age (8.2 years), retinal arteriolar %-dilation was -0.11SD (95%CI: -0.15; -0.06, P\<0.001) lower, and skin %-hyperemia was -0.10SD (-0.16; -0.05, P\<0.001) lower. Sex was not associated with retinal arteriolar %-dilation, whereas men had a -0.43SD (-0.58; -0.27, P\<0.001) lower skin %-hyperemic response as compared to women ([Fig 2](#pone.0187324.g002){ref-type="fig"}, and [S3](#pone.0187324.s006){ref-type="supplementary-material"} and [S4](#pone.0187324.s007){ref-type="supplementary-material"} Tables). Moreover, we observed a sex-by-age interaction in which the inverse association between age and skin %-hyperemia was stronger in men (-0.21SD (-0.29; -0.13), P\<0.001) than in women (-0.02SD (-0.10; 0.06), P = 0.646) (P~interaction~ = 0.002, [Fig 3](#pone.0187324.g003){ref-type="fig"}). Additional adjustment for postmenopausal status and/or hormone replacement therapy in women did not materially change these associations (data not shown).

![Associations of cardiovascular risk factors with retinal arteriolar %-dilation and skin %-hyperemia.\
Point estimates (standardized beta) and 95%CIs represent the difference (in SD) in retinal arteriolar %-dilation (black dots) and skin %-hyperemia (grey diamonds) per SD increase in the cardiovascular risk factor, men versus women, current smoker versus never smoker, or the use of antihypertensive or lipid-modifying medication versus no use. All associations were adjusted for the other risk factors, except for HbA1c, with multivariate regression. Associations of HbA1c were based on a fully adjusted regression model in which fasting plasma glucose was replaced by HbA1c. Associations of sex were additionally adjusted for height. \*P\<0.05, SD, standard deviation; CI, confidence interval; HDL, high-density lipoprotein; HbA1c, glycated hemoglobin A1c.](pone.0187324.g002){#pone.0187324.g002}

![Association between age and skin %-hyperemia according to sex.\
Regression coefficients (B) indicate the adjusted mean difference and 95% confidence interval (95%CI) in skin %-hyperemia per 1 year increase in age for men (blue line) and women (red line) (P~interaction~ = 0.002).](pone.0187324.g003){#pone.0187324.g003}

Glycemia and retinal arteriolar dilation and skin hyperemia {#sec016}
-----------------------------------------------------------

FPG (as a measure of short-term hyperglycemia) was inversely associated with retinal arteriolar %-dilation and skin %-hyperemia; per SD higher FPG (1.7 mmol/l), retinal arteriolar %-dilation was -0.12SD (95%CI: -0.17; -0.07, P\<0.001) lower, and skin %-hyperemia was -0.11SD (-0.17; -0.06, P\<0.001) lower ([Fig 2](#pone.0187324.g002){ref-type="fig"}, and [S3](#pone.0187324.s006){ref-type="supplementary-material"} and [S4](#pone.0187324.s007){ref-type="supplementary-material"} Tables). In addition, HbA1c (as a measure of long-term hyperglycemia, substituted for FPG) was inversely associated with retinal arteriolar %-dilation and skin %-hyperemia; per SD higher HbA1c (0.9 mmol/l), retinal arteriolar %-dilation was -0.14SD (95%CI: -0.19; -0.08, P\<0.001) lower, and skin %-hyperemia was -0.12SD (-0.18; -0.06, P\<0.001) lower ([S5](#pone.0187324.s008){ref-type="supplementary-material"} and [S6](#pone.0187324.s009){ref-type="supplementary-material"} Tables).

Smoking and retinal arteriolar dilation and skin hyperemia {#sec017}
----------------------------------------------------------

Current smoking (versus never smoking) was not associated with retinal arteriolar %-dilation, whereas it was associated with -0.32SD (-0.49; -0.15, P\<0.001) lower skin %-hyperemia ([Fig 2](#pone.0187324.g002){ref-type="fig"}, and [S3](#pone.0187324.s006){ref-type="supplementary-material"} and [S4](#pone.0187324.s007){ref-type="supplementary-material"} Tables). Former smoking (versus never smoking) was not associated with retinal arteriolar %-dilation and skin %-hyperemia.

Blood pressure and retinal arteriolar dilation and skin hyperemia {#sec018}
-----------------------------------------------------------------

24-h SBP was not associated with retinal arteriolar %-dilation or skin %-hyperemia ([Fig 2](#pone.0187324.g002){ref-type="fig"}, and [S3](#pone.0187324.s006){ref-type="supplementary-material"} and [S4](#pone.0187324.s007){ref-type="supplementary-material"} Tables). However, 24-h DBP (substituted for 24-h SBP) was associated with retinal arteriolar %-dilation; per SD higher 24-h DBP (7.2 mmHg), retinal arteriolar %-dilation was 0.05SD (0.00; 0.10, P = 0.040) greater. 24-h DBP was not associated with skin %-hyperemia. In addition, 24-h pulse pressure (substituted for 24-h SBP and additionally corrected for 24-h mean arterial pressure) was not associated with retinal arteriolar %-dilation, but was inversely associated with skin %-hyperemia. Per SD higher 24-h pulse pressure (8.9 mmHg), skin %-hyperemia was -0.08SD (-0.14; -0.01, P = 0.017) lower. In addition, use of antihypertensive medication was associated with numerically lower retinal arteriolar %-dilation (-0.09SD (-0.20; 0.02), P = 0.099) and skin %-hyperemia (-0.05SD (-0.17; 0.07), P = 0.396).

Waist, total-to-HDL cholesterol, and lipid-modifying medication use and retinal arteriolar dilation and skin hyperemia {#sec019}
----------------------------------------------------------------------------------------------------------------------

No significant associations were observed between waist circumference and total-to-HDL cholesterol ratio with retinal arteriolar %-dilation or skin %-hyperemia. The use of lipid-modifying medication was associated with numerically lower retinal arteriolar %-dilation (-0.11SD (-0.22; 0.01), P = 0.072)([Fig 2](#pone.0187324.g002){ref-type="fig"} and [S3 Table](#pone.0187324.s006){ref-type="supplementary-material"}).

Additional analyses {#sec020}
-------------------

Qualitatively similar associations of cardiovascular risk factors with retinal arteriolar %-dilation and skin %-hyperemia were observed in a range of additional analyses. First, when flicker light-induced increase (in MU) in retinal arteriolar diameter from baseline or heat-induced increase in skin blood flow (in PU) from skin baseline were used rather than their percentages (data not shown). Second, when waist circumference was replaced by body mass index. Third, when FPG was substituted by 2-h postload glucose or by type 2 diabetes (yes/no). Fourth, when smoking status (never/former/current) was replaced by pack-years of smoking (for retinal and skin analyses, data on pack-years of smoking were available in 1672 and 1231 individuals, respectively); pack-years of smoking was inversely associated with skin %-hyperemia -0.07 SD (-0.12; -0.01, P = 0.020). No association was found between pack-years of smoking and retinal arteriolar %-dilation (data not shown). Fifth, after additional adjustment for glucose-lowering medication (although this may be an overadjustment as the use of glucose-lowering medication was part of the definition of type 2 diabetes (78% of individuals with type 2 diabetes used glucose-lowering medication)). Sixth, after additional adjustment for a history of CVD, eGFR, urinary albumin excretion, and the presence of retinopathy (data not shown, for retinal and skin analyses, data on these additional covariates were available in 1884 and 1254 individuals respectively). Seventh, when antihypertensive medication was further specified into renin-angiotensin-aldosterone system (RAAS)-inhibiting (with or without other types of antihypertensives) and non-RAAS-inhibiting antihypertensives only (data not shown). RAAS-inhibiting antihypertensives included angiotensin-converting-enzyme, angiotensin receptor blockers and renin blockers. Eight, when individuals with other types of diabetes than type 2 diabetes were excluded (for retinal and skin analyses, 23 and 22 individuals with other types of diabetes were excluded, respectively). Next, associations of cardiovascular risk factors with retinal arteriolar %-dilation and skin %-hyperemia did not differ between individuals with and without type 2 diabetes, or between women and men (all P~interactions~\>0.10), except as noted above, for the significant interaction, with sex, of the association between age and heat-induced skin hyperemia ([Fig 3](#pone.0187324.g003){ref-type="fig"}). Last, collinearity diagnostics revealed no multicollinearity in any of the analyses (i.e. all tolerance values ≥0.10 and variance inflation factors ≤10).

Discussion {#sec021}
==========

To our knowledge this is the first population-based study which demonstrated that associations between cardiovascular risk factors and retinal and skin microvascular (endothelial) function show a pattern that is in part similar to the associations between cardiovascular risk factors and *macrovascular* function \[[@pone.0187324.ref014], [@pone.0187324.ref016]\]. Thus, older age and measures of hyperglycemia were associated with an impaired retinal and skin microvascular vasodilation response, independent of other cardiovascular risk factors. In addition, male sex and cigarette smoking were associated with impaired heat-induced skin hyperemia. In contrast to associations of obesity, blood pressure and lipid profile with *macrovascular* endothelial function \[[@pone.0187324.ref016]\], we could not confirm waist circumference, body mass index, 24-h SBP, and total-to-HDL cholesterol ratio as determinants of *microvascular* function. However, (inverse) associations of antihypertensive and lipid-modifying medication use with retinal and skin microvascular function could not be excluded ([Fig 2](#pone.0187324.g002){ref-type="fig"}). Such associations may imply that previous exposure to elevated blood pressure and dyslipidemia may affect microvascular function more than actual blood pressure and lipid profile. This would also explain why no associations of 24-h SBP and total-to-HDL cholesterol ratio with microvascular function were found.

An important mechanism by which cardiovascular risk factors affect large artery endothelial vasodilation is by impairing nitric oxide bioavailability \[[@pone.0187324.ref032]\], possibly in conjunction with adverse effects on other endothelium-dependent vasodilators (e.g. endothelium-derived hyperpolarizing factors) \[[@pone.0187324.ref033]\]. Similar mechanisms may apply to microvascular function, as microvascular vasodilation also relies on availability of endothelium-dependent vasodilators \[[@pone.0187324.ref019], [@pone.0187324.ref034]\]. Therefore, risk factor-associated impairments in flicker light-induced retinal arteriolar dilation and heat-induced skin hyperemia are both likely to be a reflection of microvascular endothelial dysfunction \[[@pone.0187324.ref019], [@pone.0187324.ref034]\], presumably in conjunction with vascular smooth muscle cell dysfunction \[[@pone.0187324.ref020], [@pone.0187324.ref021]\], and/or neuronal dysfunction \[[@pone.0187324.ref018], [@pone.0187324.ref035]\]. The correlation between these measures was weak and not statistically significant, which was likely to be explained by 1) different vessel types (relatively large arterioles in the retina vs small arterioles, capillaries, and venules in skin); 2) different outcomes (a direct stimulus-induced increase in diameter in the retina vs, an indirect estimate of vasodilation by measuring stimulus-induced increase in perfusion in skin); and 3) different stimuli used to elicit the responses (flicker light vs heat) \[[@pone.0187324.ref018], [@pone.0187324.ref019], [@pone.0187324.ref034], [@pone.0187324.ref035]\]. In addition, both measures of microvascular function have good reproducibility with intra-individual coefficients of variation of 0.91% for flicker light-induced retinal arteriolar dilation \[[@pone.0187324.ref028]\] and 8.7% for heat-induced skin hyperemia \[[@pone.0187324.ref027]\].

Associations between risk factors and microvascular responses were generally similar regardless of whether the microvascular response was obtained in retina or skin, with two exceptions. First, no difference was found between men and women in retinal arteriolar dilation, whereas heat-induced skin hyperemia was less in men than in women. This is in line with an earlier study which showed that sex differences in retinal arteriolar dilation (i.e. greater in men) were present in young individuals, but diminished after the age of 30 years \[[@pone.0187324.ref036]\]. This may explain why, in our study with an age span of 40--75 years, no difference was found. Greater retinal arteriolar dilation in younger men, as compared to age-matched women \[[@pone.0187324.ref036]\], contrasts with the beneficial effect of female sex hormones on ocular and skin blood flow \[[@pone.0187324.ref013], [@pone.0187324.ref037]\]. However, the retinal arteriolar dilation response depends on neurovascular coupling \[[@pone.0187324.ref038]\], and sex differences thus may also be influenced by the effects of sex hormones on neurons and astrocytes in the neurovascular coupling unit \[[@pone.0187324.ref039]\]. Second, retinal arteriolar dilation decreased with age in both men and women, whereas heat-induced skin hyperemia decreased with age only in men ([Fig 3](#pone.0187324.g003){ref-type="fig"}), which is consistent with an earlier report on macrovascular endothelial function \[[@pone.0187324.ref040]\]. Thus, heat-induced skin hyperemia, as compared to retinal arteriolar dilation, may be protected more by the higher levels of estrogens in women than in men \[[@pone.0187324.ref036], [@pone.0187324.ref041], [@pone.0187324.ref042]\].

Age was inversely associated with retinal arteriolar and skin microvascular dysfunction, which is in line with earlier smaller studies \[[@pone.0187324.ref008], [@pone.0187324.ref013]\], and is likely caused by reduced nitric oxide availability \[[@pone.0187324.ref043]\]. In turn, hyperglycemia may impair microvascular function through intraendothelial accumulation of glucose, increased oxidative stress and formation of advanced glycation end products \[[@pone.0187324.ref044]\]. In addition, microvascular dysfunction can cause hyperglycemia by impairing the timely access of glucose and insulin to their target tissue \[[@pone.0187324.ref045]\] and by impairing insulin secretion \[[@pone.0187324.ref046]\].

We hypothesized, but did not find, higher blood pressures to be *consistently* associated with impaired microvascular function \[[@pone.0187324.ref008], [@pone.0187324.ref011], [@pone.0187324.ref013]\], especially in the retina, which is known to be sensitive to greater flow pulsatility associated with higher blood pressure and arterial stiffening \[[@pone.0187324.ref047]\]. A potential explanation is that, in this relatively healthy and well-treated population, the blood pressure range was insufficiently broad for such associations to appear, except that 24-h pulse pressure was inversely associated with heat-induced skin hyperemia. Interestingly, use of antihypertensive medication was associated with numerically lower microvascular function, suggesting that prior exposure to high blood pressure may be important.

Current, but not former smoking was associated with impaired heat-induced skin hyperemia, which suggests that effects of smoking may be reversible. These findings are in line with an earlier report on the detrimental effect of smoking on acetylcholine-induced skin hyperemia \[[@pone.0187324.ref010]\]. Mechanistically, smoking may induce microvascular dysfunction via increased formation of reactive oxygen species and/or inhibition of nitric oxide synthase activity \[[@pone.0187324.ref048]\]. As demonstrated previously \[[@pone.0187324.ref049]\], we also did not observe a clear association of smoking with impaired retinal arteriolar dilation. Possibly, smoking affects smaller arterioles and capillaries (such as those involved in heat-induced skin hyperemia) more than the relatively large retinal arterioles we assessed \[[@pone.0187324.ref049]\].

We hypothesized \[[@pone.0187324.ref007], [@pone.0187324.ref045]\], but did not find, higher waist circumference and body mass index to be associated with impaired microvascular function as assessed here. Importantly, these findings do not imply that other functions of the microcirculation are normal in overweight or obese individuals. Indeed, earlier reports have shown waist and body mass index to be inversely associated with microvascular vasomotion \[[@pone.0187324.ref050]\], post-occlusive reactive hyperemia \[[@pone.0187324.ref051]\], and insulin-mediated vasodilation \[[@pone.0187324.ref045]\], mediated presumably by changes in visceral and perivascular \[[@pone.0187324.ref052]\] adipose tissue-derived factors, such as increased tumor necrosis factor-α and free fatty acids, and decreased adiponectin \[[@pone.0187324.ref045]\].

We expected \[[@pone.0187324.ref009], [@pone.0187324.ref053]\], but did not find, inverse associations between total-to-HDL cholesterol ratio and retinal and skin microvascular function as assessed here. Mechanistically, dyslipidemia may impair microvascular vasodilation via oxidative modifications of low-density lipoprotein cholesterol, which may cause reduced nitric oxide availability, possibly in conjunction with increased expression of endothelin-1 \[[@pone.0187324.ref053]\]. Interestingly, use of lipid-modifying medication was associated with numerically lower retinal arteriolar dilation, suggesting that prior exposure to dyslipidemia may be important.

Strengths of our study include its size and population-based design; the extensive assessment of potential determinants, including 24-h ambulatory blood pressure; the use of two independent methods to directly assess microvascular function in different microvascular beds; and the broad array of additional analyses, which all gave consistent results.

Our study also had limitations. First, the data were cross-sectional. Reverse causality obviously is not an issue for associations with age and sex, but may be especially relevant for hyperglycemia and blood pressure \[[@pone.0187324.ref054]\]. Therefore, longitudinal studies are needed. Second, we mainly focused on major cardiovascular risk factors as potential determinants; however, we do not claim to have identified all determinants, as there may be others not included in these analyses (e.g. dietary habits and physical activity). Last, the associations observed do not imply that other estimates of microvascular function, or retinal and skin microvascular responses elicited via different stimuli, such as exercise, insulin or ischemia, relate similarly to cardiovascular risk factors, as compared to flicker light-induced retinal arteriolar dilation and heat-induced skin hyperemia.

This population-based study demonstrated that associations between cardiovascular risk factors and retinal and skin *microvascular* (endothelial) function show a pattern that is in part similar to the associations between cardiovascular risk factors and *macrovascular* endothelial function. Thus, age and measures of hyperglycemia were inversely associated with retinal and skin microvascular vasodilation. In addition, male sex and cigarette smoking were associated with impaired heat-induced skin hyperemia. All associations were independent of the other cardiovascular risk factors. We could not confirm waist circumference, body mass index, 24-h SBP, and total-to-HDL cholesterol ratio as determinants of these microvascular functions. Possibly, prior exposure to high blood pressure and/or dyslipidemia is important as use of antihypertensive and/or lipid-modifying medication was associated with numerically lower microvascular function. We conclude that impairment of microvascular function may constitute a pathway through which an adverse cardiovascular risk factor pattern may increase risk of diseases, such as heart failure, stroke, and cognitive decline, that in part have a microvascular origin.
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###### Details on the assessment of cardiovascular risk factors.
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###### General characteristics for the retinal reactivity study population and individuals excluded from the analyses due to missing values.

Data are reported as mean ± SD, median \[interquartile range\], or number (percentages %) as appropriate. P-value indicates comparison between study population and individuals excluded due to missing values. SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; MU, measurement units. \* = Total number of missing values for a specific variable in the retinal reactivity study population, † = Total number of missing values for a specific variable in the population which was excluded, ‡ = (Micro)albuminuria was defined as a urinary albumin excretion of \>30 mg per 24 hours, § = 299 were excluded due to missing on potential cardiovascular risk factors.
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###### General characteristics for the skin hyperemia study population and individuals excluded from the analyses due to missing values.

Data are reported as mean ± SD, median \[interquartile range\], or number (percentages %) as appropriate. P-value indicates comparison between study population and individuals excluded due to missing values. SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; MAP, mean arterial pressure; HbA1c, glycated hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; eGFR, estimated glomerular filtration rate; PU, perfusion units. \* = Total number of missing values for a specific variable in the skin hyperemia study population, † = Total number of missing values for a specific variable in the population which was excluded, ‡ = (Micro)albuminuria was defined as a urinary albumin excretion of \>30 mg per 24 hours, § = 249 were excluded due to missing on potential cardiovascular risk factors.
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###### Multivariable-adjusted regression analyses of associations between cardiovascular risk factors with retinal arteriolar %-dilation.

Point estimates (standardized beta) and 95%CIs represent the difference (in SD) in retinal arteriolar %-dilation per SD increase in the cardiovascular risk factor, men versus women, current smoker versus never smoker, or the use of antihypertensive or lipid-modifying medication versus no use. All associations were adjusted for the other risk factors with multivariate regression. Associations of sex were additionally adjusted for height. Note that as a consequence of standardization of the continuous variables (age, waist circumference, fasting plasma glucose, total-to-HDL cholesterol, 24-h systolic blood pressure) the regression coefficient (B) for continuous variables equals the standardized beta. \*P\<0.05, SD, standard deviation; CI, confidence interval; HDL, high-density lipoprotein.
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###### Multivariable-adjusted regression analyses of associations between cardiovascular risk factors with skin %-hyperemia.

Point estimates (standardized beta) and 95%CIs represent the difference (in SD) in skin %-hyperemia per SD increase in the cardiovascular risk factor, men versus women, current smoker versus never smoker, or the use of antihypertensive or lipid-modifying medication versus no use. All associations were adjusted for the other risk factors with multivariate regression. Associations of sex were additionally adjusted for height. Note that as a consequence of standardization of the continuous variables (age, waist circumference, fasting plasma glucose, total-to-HDL cholesterol, 24-h systolic blood pressure) the regression coefficient (B) for continuous variables equals the standardized beta. \*P\<0.05, SD, standard deviation; CI, confidence interval; HDL, high-density lipoprotein.
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###### Multivariable-adjusted regression analyses of associations between cardiovascular risk factors with retinal arteriolar %-dilation with fasting plasma glucose substituted by HbA1c.

Point estimates (standardized beta) and 95%CIs represent the difference (in SD) in retinal arteriolar %-dilation per SD increase in the cardiovascular risk factor, men versus women, current smoker versus never smoker, or the use of antihypertensive or lipid-modifying medication versus no use. All associations were adjusted for the other risk factors with multivariate regression. Associations of sex were additionally adjusted for height. Note that as a consequence of standardization of the continuous variables (age, waist circumference, HbA1c, total-to-HDL cholesterol, 24-h systolic blood pressure) the regression coefficient (B) for continuous variables equals the standardized beta. \*P\<0.05, SD, standard deviation; CI, confidence interval; HDL, high-density lipoprotein.

(DOCX)

###### 

Click here for additional data file.

###### Multivariable-adjusted regression analyses of associations between cardiovascular risk factors with skin %-hyperemia with fasting plasma glucose substituted by HbA1c.

Point estimates (standardized beta) and 95%CIs represent the difference (in SD) in skin %-hyperemia per SD increase in the cardiovascular risk factor, men versus women, current smoker versus never smoker, or the use of antihypertensive or lipid-modifying medication versus no use. All associations were adjusted for the other risk factors with multivariate regression. Associations of sex were additionally adjusted for height. Note that as a consequence of standardization of the continuous variables (age, waist circumference, HbA1c, total-to-HDL cholesterol, 24-h systolic blood pressure) the regression coefficient (B) for continuous variables equals the standardized beta. \*P\<0.05, SD, standard deviation; CI, confidence interval; HDL, high-density lipoprotein.
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Click here for additional data file.
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